Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
TransCode Therapeutics Inc. (RNAZ) had Return on Equity of -130.07% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-15.05M |
|
-- |
|
-- |
|
$16.03M |
|
$-16.03M |
|
$2.81M |
|
$-13.22M |
|
$-13.22M |
|
$-13.44M |
|
$-13.44M |
|
$-13.44M |
|
$-13.44M |
|
$-16.03M |
|
$-15.98M |
|
0.69M |
|
0.69M |
|
$28.67 |
|
$28.67 |
|
| Balance Sheet Financials | |
$21.98M |
|
$0.37M |
|
$140.41M |
|
$162.40M |
|
$3.49M |
|
-- |
|
$148.57M |
|
$152.06M |
|
$10.34M |
|
$-129.71M |
|
$10.34M |
|
0.92M |
|
| Cash Flow Statement Financials | |
$-19.52M |
|
$-0.00M |
|
$31.52M |
|
$5.81M |
|
$17.81M |
|
$12.00M |
|
$0.49M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.29 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-19.52M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-130.07% |
10.36% |
|
-8.28% |
|
-130.07% |
|
$11.27 |
|
$-28.31 |
|
$-28.30 |
|